172 related articles for article (PubMed ID: 17319092)
1. Coxibs: can this class of drugs survive?
Tabrizchi R
Vasc Health Risk Manag; 2005; 1(1):5-8. PubMed ID: 17319092
[No Abstract] [Full Text] [Related]
2. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
De Vecchis R; Baldi C; Di Biase G; Ariano C; Cioppa C; Giasi A; Valente L; Cantatrione S
Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
[TBL] [Abstract][Full Text] [Related]
3. COX-2 selective inhibitors and heart health.
Simon LS; White WB
Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717
[TBL] [Abstract][Full Text] [Related]
4. Clinical use and pharmacological properties of selective COX-2 inhibitors.
Shi S; Klotz U
Eur J Clin Pharmacol; 2008 Mar; 64(3):233-52. PubMed ID: 17999057
[TBL] [Abstract][Full Text] [Related]
5. Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks.
Harv Health Lett; 2005 Mar; 30(5):1-3. PubMed ID: 16526110
[No Abstract] [Full Text] [Related]
6. [Cardiovascular events: a class effect by COX-2 inhibitors].
Araujo LF; Soeiro Ade M; Fernandes Jde L; Serrano Júnior CV
Arq Bras Cardiol; 2005 Sep; 85(3):222-9. PubMed ID: 16200274
[No Abstract] [Full Text] [Related]
7. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
[TBL] [Abstract][Full Text] [Related]
8. COX-2 inhibitors and the heart: are all coxibs the same?
Sooriakumaran P
Postgrad Med J; 2006 Apr; 82(966):242-5. PubMed ID: 16597810
[TBL] [Abstract][Full Text] [Related]
9. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Chen LC; Ashcroft DM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):762-72. PubMed ID: 17457957
[TBL] [Abstract][Full Text] [Related]
10. COX-2 inhibitors--a lesson in unexpected problems.
Drazen JM
N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947
[No Abstract] [Full Text] [Related]
11. Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects.
Heim HK; Broich K
Thromb Haemost; 2006 Oct; 96(4):423-32. PubMed ID: 17003918
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
Bäck M; Yin L; Ingelsson E
Eur Heart J; 2012 Aug; 33(15):1928-33. PubMed ID: 22108833
[TBL] [Abstract][Full Text] [Related]
13. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
[TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular risk of cyclooxygenase selective inhibitors].
Terán-Estrada L; Miranda-Limón JM; Galván-Villegas F
Rev Med Inst Mex Seguro Soc; 2008; 46(3):287-99. PubMed ID: 19133206
[TBL] [Abstract][Full Text] [Related]
15. Arthritis medicines and cardiovascular events--"house of coxibs".
Topol EJ
JAMA; 2005 Jan; 293(3):366-8. PubMed ID: 15623849
[No Abstract] [Full Text] [Related]
16. Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
Elliott WJ
Curr Hypertens Rep; 2010 Aug; 12(4):258-66. PubMed ID: 20524091
[TBL] [Abstract][Full Text] [Related]
17. [What do we know about the cardiovascular toxicity of the NSAIDs?].
Sibilia J; Deray G; Montalescot G
Presse Med; 2006 Sep; 35(9 Spec No 1):1S11-23. PubMed ID: 17078591
[TBL] [Abstract][Full Text] [Related]
18. COX-2 inhibitors and the heart: putting risk in perspective.
Bobadilla RV; Barnett EM; Randels CL
Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003
[No Abstract] [Full Text] [Related]
19. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
Kristensen LE; Jakobsen AK; Askling J; Nilsson F; Jacobsson LT
Arthritis Care Res (Hoboken); 2015 Aug; 67(8):1137-49. PubMed ID: 25623277
[TBL] [Abstract][Full Text] [Related]
20. Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib.
Ponce V; Muñoz-Bellido F; Moreno E; Laffond E; González A; Dávila I
Contact Dermatitis; 2012 Feb; 66(2):107-8. PubMed ID: 22233472
[No Abstract] [Full Text] [Related]
[Next] [New Search]
